Pure Global
NCT04842630

A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors

An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
Jiangsu HengRui Medicine Co., Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Unspecified Adult Solid Tumor, Protocol Specific
Drug/Device/Intervention
SHR-1916
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu HengRui Medicine Co., Ltd.
Location
Beijing, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 08, 2021
End date
Oct 15, 2023
Enrollment
50 participants
Primary outcome

Dose Limited Toxicity (DLT),Maximum tolerable dose (MTD),Recommended dose for phase II (RP2D)

Summary

This is a first in human, open-label, dose escalation and expansion Phase 1 study of SHR-1916
 in adult patients with locally advanced or metastatic solid tumors.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm, without specification of siteMalignant neoplasm, primary site unspecifiedCarcinoma in situ of other and unspecified genital organsMalignant neoplasm: Connective and soft tissue, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04842630
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04842630 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Recruiting. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.